EMD-34558

Single-particle
25.0 Å
EMD-34558 Deposition: 24/10/2022
Map released: 01/11/2023
Last modified: 03/04/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-34558

Immune complex of W305-2A5 IgG binding the RBD of SARS-CoV-1 2P spike protein

EMD-34558

Single-particle
25.0 Å
EMD-34558 Deposition: 24/10/2022
Map released: 01/11/2023
Last modified: 03/04/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Severe acute respiratory syndrome coronavirus, Homo sapiens
Sample: SARS-CoV-1 2P in complex with W305-2A5 IgG

Deposition Authors: Zhu JY , Zhou BN
Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection.
Wang R, Han Y, Zhang R, Zhu J, Nan X, Liu Y, Yang Z, Zhou B , Yu J, Lin Z, Li J, Chen P, Wang Y, Li Y, Liu D, Shi X, Wang X, Zhang Q, Yang YR, Li T, Zhang L
(2023) Immunity , 56 , 2635 - 2649.e6
PUBMED: 37924813
DOI: doi:10.1016/j.immuni.2023.10.007
ISSN: 1074-7613
ASTM: IUNIEH
Abstract:
The 2003 severe acute respiratory syndrome coronavirus (SARS-CoV-1) causes more severe disease than SARS-CoV-2, which is responsible for COVID-19. However, our understanding of antibody response to SARS-CoV-1 infection remains incomplete. Herein, we studied the antibody responses in 25 SARS-CoV-1 convalescent patients. Plasma neutralization was higher and lasted longer in SARS-CoV-1 patients than in severe SARS-CoV-2 patients. Among 77 monoclonal antibodies (mAbs) isolated, 60 targeted the receptor-binding domain (RBD) and formed 7 groups (RBD-1 to RBD-7) based on their distinct binding and structural profiles. Notably, RBD-7 antibodies bound to a unique RBD region interfaced with the N-terminal domain of the neighboring protomer (NTD proximal) and were more prevalent in SARS-CoV-1 patients. Broadly neutralizing antibodies for SARS-CoV-1, SARS-CoV-2, and bat and pangolin coronaviruses were also identified. These results provide further insights into the antibody response to SARS-CoV-1 and inform the design of more effective strategies against diverse human and animal coronaviruses.